Centre for Anxiety Disorders Overwaal, Lent, the Netherlands.
Int J Geriatr Psychiatry. 2012 Feb;27(2):146-50. doi: 10.1002/gps.2700. Epub 2011 Mar 30.
This study aims to evaluate the differential predictive values of age, age of onset and duration of illness on paroxetine and cognitive-behavioural therapy (CBT) outcome in late-life panic disorder with agoraphobia.
Patients 60 years and older with a confirmed diagnosis of panic disorder with agoraphobia (n = 49) were randomly assigned to paroxetine (40 mg/day) treatment, individual CBT or a waiting-list control condition. Multiple regression analyses were conducted per treatment arm with post-treatment avoidance behaviour and agoraphobic cognitions as the dependent variables.
Higher age at onset and shorter duration of illness were predictors of superior outcomes following CBT, although these variables did not influence the treatment effects of paroxetine.
In late-life agoraphobic panic disorder, chronological age has no impact on treatment modality outcome. In older patients with a late disease onset or shorter duration of illness, CBT is to be preferred over paroxetine, whereas paroxetine might be the treatment of choice for older people with an early onset and short duration of illness.
本研究旨在评估年龄、发病年龄和病程对帕罗西汀和认知行为疗法(CBT)治疗老年惊恐障碍伴广场恐怖症结局的差异预测价值。
本研究共纳入 49 例确诊为惊恐障碍伴广场恐怖症的 60 岁及以上患者,他们被随机分配至帕罗西汀(40mg/天)治疗、个体 CBT 或等待名单对照条件。采用多元回归分析,以治疗后回避行为和广场恐怖认知作为因变量,分别对每个治疗组进行分析。
发病年龄较高和病程较短是 CBT 后疗效较好的预测因素,但这些变量并不影响帕罗西汀的治疗效果。
在老年惊恐障碍伴广场恐怖症中,年龄对治疗方式的结局没有影响。对于发病年龄较晚或病程较短的老年患者,CBT 优于帕罗西汀,而对于发病年龄较早和病程较短的老年患者,帕罗西汀可能是首选治疗方法。